Pfizer Corporation

David Edmonds

David Andrew Griffith

Mark Edward Flanagan

David W Piotrowski

Roger B Ruggeri

Kentaro Futatsugi

Scott William Bagley

Kim Huard

Chris Limberakis

Alan Martin Mathiowetz

John M Curto

Gary Erik Aspnes

Matthew Scott Dowling

Wenhua Jiao

Gajendra Ingle

Edward L Conn

Allyn T Londregan

Yajing Lian

Andrew John Bessire

Amit Sumant Kalgutkar

Timothy Frank Ryder

Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

GLP-1 receptor agonists and uses thereof

Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

The present invention provides compounds of Formula XA-1, XA-2, XA-3, XA-4, XA-5, or XA-6, or metabolites of Compound 1 or metabolites of a compound of Formula I, PA-I, or PA-III, including compositions and salts thereof, which are useful in the prevention and/or treatment of a disease or disorder such as T2DM, obesity, or NASH, as well as analytical methods related to the administration of Compound 1 or a compound of Formula I, PA-1, or PA-III.

Metabolites of GLP1R agonists

Growing community of inventors

Basel, Switzerland

David Edmonds